Pfizer, the world's largest drugmaker, is scheduled to repo
rt fourth-quarter results before the opening bell on Wednesday, February 3.
The consensus First Call EPS estimate stands at $0.50 compared to last year's gain of $0.65, while revenue is expected to increase by 29.7% to $15.97 billion.
What follows are some facts and figures on how Pfizer shares traded in the most recent earnings reports.
Beat revenue estimates for 4 of the past 8 quarters
Beat EPS estimates for 7 of the past 8 quarters
Beat annual EPS estimates for 3 of the past 5 years
Dollar impact? In 2008, 58% of revenue was derived from outside the United States
Pfizer shares are up 3% in 2010, and 49% since the March low
Competitors' Performance in 2010: Merck +5%, Novartis -0.7%, Amgen +4% and Biogen Idec +0.8%
Pfizer shares hit a new 52-week high of $20.36 on January 20, 2010
The company's shares are trading 0.8% above their 50-day moving average
Stock Performance By The Numbers
- In the past 8 quarters, Pfizer shares rose 1.57%, on average, the day before the company reported its quarterly results
- Pfizer shares have a bearish trend that peaks 4 days after earnings. It has declined 8 times after the past 10 earnings reports, posting an overall average loss of 2% (MarketHistory.com)
S&P Healthcare Sector:
- Best performing sector so far in 2010, up 0.9%
- Leaders year-to-date: Humana +11%, Genzyme +10.6% and Gilead Sciences +10.5%
- Losers year-to-date: Forest Laboratories -8%, Allergan -8% and Waters Corp. -7.7%
Earning Estimates Source: CNBC & Thomson Reuters